[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fqjZZDgvn4yZIuoI113_kTdZyJOHGX82HVBQFT-MHkKU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":45,"rows":52},"Rockefeller University",[4],122,false,6,2,6015,60,[13,16,19,22,24,26,29,32],{"name":14,"count":15},"Obesity",19,{"name":17,"count":18},"HIV Infections",9,{"name":20,"count":21},"Psoriasis",7,{"name":23,"count":21},"Healthy Volunteers",{"name":25,"count":8},"Human Immunodeficiency Virus",{"name":27,"count":28},"Healthy",5,{"name":30,"count":31},"Hepatitis C",4,{"name":33,"count":31},"Insulin Resistance",[35,40],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05709483","Predictors of Aspirin Failure in Preeclampsia Prevention","2026-11-01","Aspirin",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05856890","HepB mAb19 in Individuals With Chronic Hepatitis B Infection","2027-12-01","HepB mAb19",[46,47,48,49,50,51],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[53,79,100,126,151,175,200,225,299,333,351,369,394,412,437,461,486,504,528,552,604,631,657,682,700,727,745,763,781,806,824,842,872,890,908,926,944,962,989,1007,1025,1051,1076,1094,1117,1140,1162,1185,1203,1229,1272,1296,1319,1341,1364,1388,1422,1456,1488,1519,1543,1566,1589,1613,1637,1655,1673,1691,1709,1733,1754,1775],{"intervention":44,"totalTrials":54,"cells":55},1,{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":71,"PHASE3":73,"PHASE4":75,"NA":77},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":54,"soonestReadout":43},[61],{"nctId":41,"briefTitle":42,"status":62,"phases":63,"primaryCompletion":43,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":70},"RECRUITING",[47],"2028-03-30","2023-08-07",37,[68,69],"Hepatitis b Virus","Hepatitis B",[44],{"trials":72,"activeCount":58},[],{"trials":74,"activeCount":58},[],{"trials":76,"activeCount":58},[],{"trials":78,"activeCount":58},[],{"intervention":39,"totalTrials":54,"cells":80},{"EARLY_PHASE1":81,"PHASE1":90,"PHASE2":92,"PHASE3":94,"PHASE4":96,"NA":98},{"trials":82,"activeCount":54,"soonestReadout":38},[83],{"nctId":36,"briefTitle":37,"status":62,"phases":84,"primaryCompletion":38,"completion":38,"start":85,"enrollment":86,"conditions":87,"interventions":89},[46],"2023-04-13",130,[88],"Preeclampsia",[39],{"trials":91,"activeCount":58},[],{"trials":93,"activeCount":58},[],{"trials":95,"activeCount":58},[],{"trials":97,"activeCount":58},[],{"trials":99,"activeCount":58},[],{"intervention":101,"totalTrials":54,"cells":102},"Recombivax",{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":109,"PHASE4":111,"NA":124},{"trials":104,"activeCount":58},[],{"trials":106,"activeCount":58},[],{"trials":108,"activeCount":58},[],{"trials":110,"activeCount":58},[],{"trials":112,"activeCount":58},[113],{"nctId":114,"briefTitle":115,"status":116,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":123},"NCT02429583","Effects of Persistent Innate Immune Activation on Vaccine Efficacy","TERMINATED",[50],"2018-11","2015-05-08",24,[122],"Hepatitis C Infection",[101],{"trials":125,"activeCount":58},[],{"intervention":127,"totalTrials":54,"cells":128},"Statins",{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":149},{"trials":130,"activeCount":58},[],{"trials":132,"activeCount":58},[],{"trials":134,"activeCount":58},[],{"trials":136,"activeCount":58},[],{"trials":138,"activeCount":58},[139],{"nctId":140,"briefTitle":141,"status":116,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":148},"NCT00850460","Quality of Life in Patients With Statin-Associated Myopathy",[50],"2013-02","2009-02",14,[147],"Statin Adverse Reaction",[127],{"trials":150,"activeCount":58},[],{"intervention":152,"totalTrials":54,"cells":153},"Harvoni",{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":162,"NA":173},{"trials":155,"activeCount":58},[],{"trials":157,"activeCount":58},[],{"trials":159,"activeCount":58},[],{"trials":161,"activeCount":58},[],{"trials":163,"activeCount":58},[164],{"nctId":165,"briefTitle":166,"status":167,"phases":168,"primaryCompletion":169,"completion":169,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT02347345","Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs","COMPLETED",[50],"2016-11-15",34,[30],[152],{"trials":174,"activeCount":58},[],{"intervention":176,"totalTrials":54,"cells":177},"Amoxicillin Oral",{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":198},{"trials":179,"activeCount":58},[],{"trials":181,"activeCount":58},[],{"trials":183,"activeCount":58},[],{"trials":185,"activeCount":58},[],{"trials":187,"activeCount":58},[188],{"nctId":189,"briefTitle":190,"status":167,"phases":191,"primaryCompletion":192,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT05834036","Effect of Antibiotics on Enteric Neurons and Glia",[50],"2023-11-09","2023-06-23",10,[196],"Antibiotic Enterocolitis",[176],{"trials":199,"activeCount":58},[],{"intervention":201,"totalTrials":54,"cells":202},"Efalizumab",{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":221,"NA":223},{"trials":204,"activeCount":58},[],{"trials":206,"activeCount":58},[],{"trials":208,"activeCount":58},[],{"trials":210,"activeCount":58},[211],{"nctId":212,"briefTitle":213,"status":167,"phases":214,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":220},"NCT00115076","Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis",[49],"2009-05-18","2011-04-06","2003-08-04",31,[20],[201],{"trials":222,"activeCount":58},[],{"trials":224,"activeCount":58},[],{"intervention":226,"totalTrials":8,"cells":227},"3BNC117",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":261,"PHASE3":293,"PHASE4":295,"NA":297},{"trials":229,"activeCount":58},[],{"trials":231,"activeCount":58},[232,243,251],{"nctId":233,"briefTitle":234,"status":167,"phases":235,"primaryCompletion":236,"completion":237,"start":238,"enrollment":170,"conditions":239,"interventions":241},"NCT02825797","3BNC117 and 10-1074 in HIV-infected Individuals",[47],"2018-08-01","2018-08-15","2016-06",[240],"Human Immunodeficiency Virus (HIV)",[226,242],"10-1074",{"nctId":244,"briefTitle":245,"status":167,"phases":246,"primaryCompletion":247,"completion":247,"start":248,"enrollment":120,"conditions":249,"interventions":250},"NCT02824536","3BNC117 and 10-1074 in HIV Uninfected Adults",[47],"2018-01-09","2016-06-23",[25],[226,242],{"nctId":252,"briefTitle":253,"status":167,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":260},"NCT03526848","3BNC117 and 10-1074 in ART-treated Individuals",[47],"2021-09-30","2022-02-11","2018-06-05",26,[25],[226,242],{"trials":262,"activeCount":58},[263,273,283],{"nctId":264,"briefTitle":265,"status":167,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT02446847","3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption",[48],"2017-03-25","2015-03-11",16,[271],"HIV-1 Infection",[226],{"nctId":274,"briefTitle":275,"status":167,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":282},"NCT02588586","A Study of the Safety and Antiretroviral Activity of 3BNC117",[48],"2018-02","2018-04","2015-10",17,[271],[226],{"nctId":284,"briefTitle":285,"status":167,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":291},"NCT02850016","Romidepsin Plus 3BNC117 Phase 2a Study",[48],"2020-12-31","2017-01-06",48,[240],[226,292],"Romidepsin",{"trials":294,"activeCount":58},[],{"trials":296,"activeCount":58},[],{"trials":298,"activeCount":58},[],{"intervention":300,"totalTrials":9,"cells":301},"Daclizumab",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":327,"PHASE4":329,"NA":331},{"trials":303,"activeCount":58},[],{"trials":305,"activeCount":58},[],{"trials":307,"activeCount":58},[308,320],{"nctId":309,"briefTitle":310,"status":167,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":317},"NCT00050648","To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris",[47,48],"2004-09","2008-04","1997-10",20,[20],[300,318,319],"Cyclosporine","cyclosporine and Daclizumab",{"nctId":321,"briefTitle":322,"status":167,"phases":323,"primaryCompletion":324,"completion":313,"start":314,"enrollment":8,"conditions":325,"interventions":326},"NCT00050661","To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris",[47,48],"2004-04",[20],[300],{"trials":328,"activeCount":58},[],{"trials":330,"activeCount":58},[],{"trials":332,"activeCount":58},[],{"intervention":318,"totalTrials":54,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":345,"PHASE4":347,"NA":349},{"trials":336,"activeCount":58},[],{"trials":338,"activeCount":58},[],{"trials":340,"activeCount":58},[341],{"nctId":309,"briefTitle":310,"status":167,"phases":342,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":343,"interventions":344},[47,48],[20],[300,318,319],{"trials":346,"activeCount":58},[],{"trials":348,"activeCount":58},[],{"trials":350,"activeCount":58},[],{"intervention":319,"totalTrials":54,"cells":352},{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":363,"PHASE4":365,"NA":367},{"trials":354,"activeCount":58},[],{"trials":356,"activeCount":58},[],{"trials":358,"activeCount":58},[359],{"nctId":309,"briefTitle":310,"status":167,"phases":360,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":361,"interventions":362},[47,48],[20],[300,318,319],{"trials":364,"activeCount":58},[],{"trials":366,"activeCount":58},[],{"trials":368,"activeCount":58},[],{"intervention":370,"totalTrials":54,"cells":371},"vaccine vehicle only",{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":373,"activeCount":58},[],{"trials":375,"activeCount":58},[],{"trials":377,"activeCount":58},[378],{"nctId":379,"briefTitle":380,"status":167,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":120,"conditions":384,"interventions":386},"NCT00289341","Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.",[47,48],"2008-11","2002-03",[385],"Prostate Cancer",[370,387],"DC\u002FLNCaP",{"trials":389,"activeCount":58},[],{"trials":391,"activeCount":58},[],{"trials":393,"activeCount":58},[],{"intervention":387,"totalTrials":54,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":406,"PHASE4":408,"NA":410},{"trials":397,"activeCount":58},[],{"trials":399,"activeCount":58},[],{"trials":401,"activeCount":58},[402],{"nctId":379,"briefTitle":380,"status":167,"phases":403,"primaryCompletion":382,"completion":382,"start":383,"enrollment":120,"conditions":404,"interventions":405},[47,48],[385],[370,387],{"trials":407,"activeCount":58},[],{"trials":409,"activeCount":58},[],{"trials":411,"activeCount":58},[],{"intervention":413,"totalTrials":54,"cells":414},"Leptin",{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":431,"PHASE4":433,"NA":435},{"trials":416,"activeCount":58},[],{"trials":418,"activeCount":58},[],{"trials":420,"activeCount":58},[421],{"nctId":422,"briefTitle":423,"status":167,"phases":424,"primaryCompletion":425,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":430},"NCT00050791","Effects of Leptin Treatment on Weight Loss",[48],"2006-11","2009-06","2001-03",40,[14],[413],{"trials":432,"activeCount":58},[],{"trials":434,"activeCount":58},[],{"trials":436,"activeCount":58},[],{"intervention":438,"totalTrials":54,"cells":439},"Potent HAART during acute or early HIV-1 infection",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":455,"PHASE4":457,"NA":459},{"trials":441,"activeCount":58},[],{"trials":443,"activeCount":58},[],{"trials":445,"activeCount":58},[446],{"nctId":447,"briefTitle":448,"status":167,"phases":449,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":454},"NCT00219986","Phase I\u002FII, Open-Label Trial of Three Monoclonal Antibodies",[47,48],"2005-09","2003-10",12,[17],[438],{"trials":456,"activeCount":58},[],{"trials":458,"activeCount":58},[],{"trials":460,"activeCount":58},[],{"intervention":462,"totalTrials":54,"cells":463},"Ustekinumab",{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":465,"activeCount":58},[],{"trials":467,"activeCount":58},[],{"trials":469,"activeCount":58},[470],{"nctId":471,"briefTitle":472,"status":167,"phases":473,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":479},"NCT01806662","Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis",[48],"2015-03","2013-03",32,[478],"Atopic Dermatitis",[462],{"trials":481,"activeCount":58},[],{"trials":483,"activeCount":58},[],{"trials":485,"activeCount":58},[],{"intervention":292,"totalTrials":54,"cells":487},{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":489,"activeCount":58},[],{"trials":491,"activeCount":58},[],{"trials":493,"activeCount":58},[494],{"nctId":284,"briefTitle":285,"status":167,"phases":495,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":496,"interventions":497},[48],[240],[226,292],{"trials":499,"activeCount":58},[],{"trials":501,"activeCount":58},[],{"trials":503,"activeCount":58},[],{"intervention":505,"totalTrials":54,"cells":506},"autologous dendritic cell vaccine",{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":522,"PHASE4":524,"NA":526},{"trials":508,"activeCount":58},[],{"trials":510,"activeCount":58},[],{"trials":512,"activeCount":58},[513],{"nctId":514,"briefTitle":515,"status":167,"phases":516,"primaryCompletion":517,"completion":474,"start":518,"enrollment":519,"conditions":520,"interventions":521},"NCT00345293","Dendritic Cell Vaccine Study (DC\u002FPC3) for Prostate Cancer",[47,48],"2013-12","2006-06",13,[385],[505],{"trials":523,"activeCount":58},[],{"trials":525,"activeCount":58},[],{"trials":527,"activeCount":58},[],{"intervention":529,"totalTrials":54,"cells":530},"ILV-094",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":546,"PHASE4":548,"NA":550},{"trials":532,"activeCount":58},[],{"trials":534,"activeCount":58},[],{"trials":536,"activeCount":58},[537],{"nctId":538,"briefTitle":539,"status":167,"phases":540,"primaryCompletion":541,"completion":542,"start":543,"enrollment":11,"conditions":544,"interventions":545},"NCT01941537","Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis",[48],"2016-02","2019-01","2013-10",[478],[529],{"trials":547,"activeCount":58},[],{"trials":549,"activeCount":58},[],{"trials":551,"activeCount":58},[],{"intervention":553,"totalTrials":31,"cells":554},"3BNC117-LS",{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":556,"activeCount":58},[],{"trials":558,"activeCount":58},[559,567,579,588],{"nctId":560,"briefTitle":561,"status":167,"phases":562,"primaryCompletion":287,"completion":287,"start":563,"enrollment":564,"conditions":565,"interventions":566},"NCT03254277","3BNC117-LS First-in-Human Phase 1 Study",[47],"2017-09-13",43,[25],[553],{"nctId":568,"briefTitle":569,"status":167,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":576},"NCT05245292","3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)",[47],"2025-12-09","2025-12-31","2022-12-07",28,[25],[553,577,578],"10-1074-LS","N803",{"nctId":580,"briefTitle":581,"status":167,"phases":582,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":587},"NCT03554408","First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS",[47],"2021-02-04","2018-06-20",77,[25],[577,577,553,553],{"nctId":589,"briefTitle":590,"status":167,"phases":591,"primaryCompletion":592,"completion":256,"start":593,"enrollment":8,"conditions":594,"interventions":595},"NCT04250636","3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals",[47],"2022-01-21","2020-10-13",[25],[553,577],{"trials":597,"activeCount":58},[],{"trials":599,"activeCount":58},[],{"trials":601,"activeCount":58},[],{"trials":603,"activeCount":58},[],{"intervention":577,"totalTrials":605,"cells":606},3,{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":608,"activeCount":58},[],{"trials":610,"activeCount":58},[611,615,619],{"nctId":568,"briefTitle":569,"status":167,"phases":612,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":613,"interventions":614},[47],[25],[553,577,578],{"nctId":580,"briefTitle":581,"status":167,"phases":616,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":617,"interventions":618},[47],[25],[577,577,553,553],{"nctId":589,"briefTitle":590,"status":167,"phases":620,"primaryCompletion":592,"completion":256,"start":593,"enrollment":8,"conditions":621,"interventions":622},[47],[25],[553,577],{"trials":624,"activeCount":58},[],{"trials":626,"activeCount":58},[],{"trials":628,"activeCount":58},[],{"trials":630,"activeCount":58},[],{"intervention":242,"totalTrials":605,"cells":632},{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":634,"activeCount":58},[],{"trials":636,"activeCount":58},[637,641,645],{"nctId":233,"briefTitle":234,"status":167,"phases":638,"primaryCompletion":236,"completion":237,"start":238,"enrollment":170,"conditions":639,"interventions":640},[47],[240],[226,242],{"nctId":244,"briefTitle":245,"status":167,"phases":642,"primaryCompletion":247,"completion":247,"start":248,"enrollment":120,"conditions":643,"interventions":644},[47],[25],[226,242],{"nctId":252,"briefTitle":253,"status":167,"phases":646,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":647,"interventions":648},[47],[25],[226,242],{"trials":650,"activeCount":58},[],{"trials":652,"activeCount":58},[],{"trials":654,"activeCount":58},[],{"trials":656,"activeCount":58},[],{"intervention":658,"totalTrials":54,"cells":659},"C144-LS and C-135-LS",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":674,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":661,"activeCount":58},[],{"trials":663,"activeCount":58},[664],{"nctId":665,"briefTitle":666,"status":167,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT04700163","RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers",[47],"2022-02-02","2021-01-11",23,[672],"Covid19",[658],{"trials":675,"activeCount":58},[],{"trials":677,"activeCount":58},[],{"trials":679,"activeCount":58},[],{"trials":681,"activeCount":58},[],{"intervention":578,"totalTrials":54,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":685,"activeCount":58},[],{"trials":687,"activeCount":58},[688],{"nctId":568,"briefTitle":569,"status":167,"phases":689,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":690,"interventions":691},[47],[25],[553,577,578],{"trials":693,"activeCount":58},[],{"trials":695,"activeCount":58},[],{"trials":697,"activeCount":58},[],{"trials":699,"activeCount":58},[],{"intervention":701,"totalTrials":54,"cells":702},"DNA methylation analysis",{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":719,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":704,"activeCount":58},[],{"trials":706,"activeCount":58},[707],{"nctId":708,"briefTitle":709,"status":167,"phases":710,"primaryCompletion":711,"start":712,"enrollment":315,"conditions":713,"interventions":715},"NCT00611000","Effect of Folate on DNA in Colon Tissue and Blood Samples From Patients at Increased Risk of Developing Colorectal Neoplasia",[47],"2006-01","2003-06",[714],"Colorectal Cancer",[701,716,717,718],"gene expression analysis","microarray analysis","polymorphism analysis",{"trials":720,"activeCount":58},[],{"trials":722,"activeCount":58},[],{"trials":724,"activeCount":58},[],{"trials":726,"activeCount":58},[],{"intervention":716,"totalTrials":54,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":743},{"trials":730,"activeCount":58},[],{"trials":732,"activeCount":58},[733],{"nctId":708,"briefTitle":709,"status":167,"phases":734,"primaryCompletion":711,"start":712,"enrollment":315,"conditions":735,"interventions":736},[47],[714],[701,716,717,718],{"trials":738,"activeCount":58},[],{"trials":740,"activeCount":58},[],{"trials":742,"activeCount":58},[],{"trials":744,"activeCount":58},[],{"intervention":717,"totalTrials":54,"cells":746},{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":748,"activeCount":58},[],{"trials":750,"activeCount":58},[751],{"nctId":708,"briefTitle":709,"status":167,"phases":752,"primaryCompletion":711,"start":712,"enrollment":315,"conditions":753,"interventions":754},[47],[714],[701,716,717,718],{"trials":756,"activeCount":58},[],{"trials":758,"activeCount":58},[],{"trials":760,"activeCount":58},[],{"trials":762,"activeCount":58},[],{"intervention":718,"totalTrials":54,"cells":764},{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":766,"activeCount":58},[],{"trials":768,"activeCount":58},[769],{"nctId":708,"briefTitle":709,"status":167,"phases":770,"primaryCompletion":711,"start":712,"enrollment":315,"conditions":771,"interventions":772},[47],[714],[701,716,717,718],{"trials":774,"activeCount":58},[],{"trials":776,"activeCount":58},[],{"trials":778,"activeCount":58},[],{"trials":780,"activeCount":58},[],{"intervention":782,"totalTrials":54,"cells":783},"DC\u002FAAT",{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":798,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":785,"activeCount":58},[],{"trials":787,"activeCount":58},[788],{"nctId":789,"briefTitle":790,"status":167,"phases":791,"primaryCompletion":517,"completion":517,"start":792,"enrollment":15,"conditions":793,"interventions":795},"NCT00893945","Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors",[47],"2007-06",[794],"Brain Tumors",[782,796,797],"DC\u002FAAT-Flu","DC\u002FKLH",{"trials":799,"activeCount":58},[],{"trials":801,"activeCount":58},[],{"trials":803,"activeCount":58},[],{"trials":805,"activeCount":58},[],{"intervention":796,"totalTrials":54,"cells":807},{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":816,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":809,"activeCount":58},[],{"trials":811,"activeCount":58},[812],{"nctId":789,"briefTitle":790,"status":167,"phases":813,"primaryCompletion":517,"completion":517,"start":792,"enrollment":15,"conditions":814,"interventions":815},[47],[794],[782,796,797],{"trials":817,"activeCount":58},[],{"trials":819,"activeCount":58},[],{"trials":821,"activeCount":58},[],{"trials":823,"activeCount":58},[],{"intervention":797,"totalTrials":54,"cells":825},{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":840},{"trials":827,"activeCount":58},[],{"trials":829,"activeCount":58},[830],{"nctId":789,"briefTitle":790,"status":167,"phases":831,"primaryCompletion":517,"completion":517,"start":792,"enrollment":15,"conditions":832,"interventions":833},[47],[794],[782,796,797],{"trials":835,"activeCount":58},[],{"trials":837,"activeCount":58},[],{"trials":839,"activeCount":58},[],{"trials":841,"activeCount":58},[],{"intervention":843,"totalTrials":54,"cells":844},"1 mg\u002Fkg, single dose IV administration of 3BNC117",{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":864,"PHASE3":866,"PHASE4":868,"NA":870},{"trials":846,"activeCount":58},[],{"trials":848,"activeCount":58},[849],{"nctId":850,"briefTitle":851,"status":167,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":856,"interventions":858},"NCT02018510","A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117",[47],"2016-01","2014-01",49,[27,857],"HIV",[843,859,860,861,862,863],"3 mg\u002Fkg, single dose IV administration of 3BNC117","10 mg\u002Fkg, single dose IV administration of 3BNC117","30 mg\u002Fkg, single dose IV administration of 3BNC117","10 mg\u002Fkg, two doses IV of 3BNC117","30 mg\u002Fkg, two doses IV of 3BNC117",{"trials":865,"activeCount":58},[],{"trials":867,"activeCount":58},[],{"trials":869,"activeCount":58},[],{"trials":871,"activeCount":58},[],{"intervention":859,"totalTrials":54,"cells":873},{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":875,"activeCount":58},[],{"trials":877,"activeCount":58},[878],{"nctId":850,"briefTitle":851,"status":167,"phases":879,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":880,"interventions":881},[47],[27,857],[843,859,860,861,862,863],{"trials":883,"activeCount":58},[],{"trials":885,"activeCount":58},[],{"trials":887,"activeCount":58},[],{"trials":889,"activeCount":58},[],{"intervention":860,"totalTrials":54,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":900,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":893,"activeCount":58},[],{"trials":895,"activeCount":58},[896],{"nctId":850,"briefTitle":851,"status":167,"phases":897,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":898,"interventions":899},[47],[27,857],[843,859,860,861,862,863],{"trials":901,"activeCount":58},[],{"trials":903,"activeCount":58},[],{"trials":905,"activeCount":58},[],{"trials":907,"activeCount":58},[],{"intervention":861,"totalTrials":54,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":918,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":911,"activeCount":58},[],{"trials":913,"activeCount":58},[914],{"nctId":850,"briefTitle":851,"status":167,"phases":915,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":916,"interventions":917},[47],[27,857],[843,859,860,861,862,863],{"trials":919,"activeCount":58},[],{"trials":921,"activeCount":58},[],{"trials":923,"activeCount":58},[],{"trials":925,"activeCount":58},[],{"intervention":862,"totalTrials":54,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":929,"activeCount":58},[],{"trials":931,"activeCount":58},[932],{"nctId":850,"briefTitle":851,"status":167,"phases":933,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":934,"interventions":935},[47],[27,857],[843,859,860,861,862,863],{"trials":937,"activeCount":58},[],{"trials":939,"activeCount":58},[],{"trials":941,"activeCount":58},[],{"trials":943,"activeCount":58},[],{"intervention":863,"totalTrials":54,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":954,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":947,"activeCount":58},[],{"trials":949,"activeCount":58},[950],{"nctId":850,"briefTitle":851,"status":167,"phases":951,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":952,"interventions":953},[47],[27,857],[843,859,860,861,862,863],{"trials":955,"activeCount":58},[],{"trials":957,"activeCount":58},[],{"trials":959,"activeCount":58},[],{"trials":961,"activeCount":58},[],{"intervention":963,"totalTrials":54,"cells":964},"3 mg\u002Fkg, single dose IV administration of 10-1074",{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":987},{"trials":966,"activeCount":58},[],{"trials":968,"activeCount":58},[969],{"nctId":970,"briefTitle":971,"status":167,"phases":972,"primaryCompletion":973,"completion":974,"start":975,"enrollment":976,"conditions":977,"interventions":978},"NCT02511990","A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074",[47],"2016-12","2017-12","2015-07",33,[27,857],[963,979,980],"10 mg\u002Fkg, single dose IV administration of 10-1074","30 mg\u002Fkg, single dose IV administration of 10-1074",{"trials":982,"activeCount":58},[],{"trials":984,"activeCount":58},[],{"trials":986,"activeCount":58},[],{"trials":988,"activeCount":58},[],{"intervention":979,"totalTrials":54,"cells":990},{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":992,"activeCount":58},[],{"trials":994,"activeCount":58},[995],{"nctId":970,"briefTitle":971,"status":167,"phases":996,"primaryCompletion":973,"completion":974,"start":975,"enrollment":976,"conditions":997,"interventions":998},[47],[27,857],[963,979,980],{"trials":1000,"activeCount":58},[],{"trials":1002,"activeCount":58},[],{"trials":1004,"activeCount":58},[],{"trials":1006,"activeCount":58},[],{"intervention":980,"totalTrials":54,"cells":1008},{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":1010,"activeCount":58},[],{"trials":1012,"activeCount":58},[1013],{"nctId":970,"briefTitle":971,"status":167,"phases":1014,"primaryCompletion":973,"completion":974,"start":975,"enrollment":976,"conditions":1015,"interventions":1016},[47],[27,857],[963,979,980],{"trials":1018,"activeCount":58},[],{"trials":1020,"activeCount":58},[],{"trials":1022,"activeCount":58},[],{"trials":1024,"activeCount":58},[],{"intervention":1026,"totalTrials":54,"cells":1027},"Calcium and Calcitriol",{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1043,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1029,"activeCount":58},[],{"trials":1031,"activeCount":58},[1032],{"nctId":1033,"briefTitle":1034,"status":167,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":194,"conditions":1038,"interventions":1042},"NCT00298545","Effect of Vitamin D and Calcium on Genes in the Colon",[47],"2009-05","2005-11",[1039,1040,1041],"Colorectal Polyps","Colorectal Adenoma","Adenocarcinoma",[1026],{"trials":1044,"activeCount":58},[],{"trials":1046,"activeCount":58},[],{"trials":1048,"activeCount":58},[],{"trials":1050,"activeCount":58},[],{"intervention":1052,"totalTrials":54,"cells":1053},"DCVax-001",{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1068,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1055,"activeCount":58},[],{"trials":1057,"activeCount":58},[1058],{"nctId":1059,"briefTitle":1060,"status":167,"phases":1061,"primaryCompletion":1062,"completion":1062,"start":1063,"enrollment":564,"conditions":1064,"interventions":1066},"NCT01127464","DCVax Plus Poly ICLC in Healthy Volunteers",[47],"2012-11","2010-05",[271,1065,23],"HIV Infection",[1052,1067],"Poly-ICLC",{"trials":1069,"activeCount":58},[],{"trials":1071,"activeCount":58},[],{"trials":1073,"activeCount":58},[],{"trials":1075,"activeCount":58},[],{"intervention":1067,"totalTrials":54,"cells":1077},{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1086,"PHASE3":1088,"PHASE4":1090,"NA":1092},{"trials":1079,"activeCount":58},[],{"trials":1081,"activeCount":58},[1082],{"nctId":1059,"briefTitle":1060,"status":167,"phases":1083,"primaryCompletion":1062,"completion":1062,"start":1063,"enrollment":564,"conditions":1084,"interventions":1085},[47],[271,1065,23],[1052,1067],{"trials":1087,"activeCount":58},[],{"trials":1089,"activeCount":58},[],{"trials":1091,"activeCount":58},[],{"trials":1093,"activeCount":58},[],{"intervention":1095,"totalTrials":54,"cells":1096},"Hiltonol",{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1098,"activeCount":58},[],{"trials":1100,"activeCount":58},[1101],{"nctId":1102,"briefTitle":1103,"status":167,"phases":1104,"primaryCompletion":1105,"completion":1105,"start":1106,"enrollment":120,"conditions":1107,"interventions":1108},"NCT01012700","Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers",[47],"2010-04","2009-11",[23],[1095],{"trials":1110,"activeCount":58},[],{"trials":1112,"activeCount":58},[],{"trials":1114,"activeCount":58},[],{"trials":1116,"activeCount":58},[],{"intervention":1118,"totalTrials":54,"cells":1119},"Poly ICLC",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1132,"PHASE3":1134,"PHASE4":1136,"NA":1138},{"trials":1121,"activeCount":58},[],{"trials":1123,"activeCount":58},[1124],{"nctId":1125,"briefTitle":1126,"status":167,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":1129,"enrollment":8,"conditions":1130,"interventions":1131},"NCT01299662","Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers",[47],"2011-09","2011-06",[23],[1118],{"trials":1133,"activeCount":58},[],{"trials":1135,"activeCount":58},[],{"trials":1137,"activeCount":58},[],{"trials":1139,"activeCount":58},[],{"intervention":1141,"totalTrials":54,"cells":1142},"MVA-CMDR",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1154,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1144,"activeCount":58},[],{"trials":1146,"activeCount":58},[1147],{"nctId":1148,"briefTitle":1149,"status":167,"phases":1150,"primaryCompletion":1151,"completion":1151,"start":854,"enrollment":145,"conditions":1152,"interventions":1153},"NCT01889719","A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR",[47],"2015-05",[857],[1141],{"trials":1155,"activeCount":58},[],{"trials":1157,"activeCount":58},[],{"trials":1159,"activeCount":58},[],{"trials":1161,"activeCount":58},[],{"intervention":1163,"totalTrials":54,"cells":1164},"GLA-AF",{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1177,"PHASE3":1179,"PHASE4":1181,"NA":1183},{"trials":1166,"activeCount":58},[],{"trials":1168,"activeCount":58},[1169],{"nctId":1170,"briefTitle":1171,"status":167,"phases":1172,"primaryCompletion":475,"completion":475,"start":1173,"enrollment":476,"conditions":1174,"interventions":1175},"NCT01397604","The Effects of GLA on Human Volunteers",[47],"2011-07",[23],[1163,1176],"GLA-SE",{"trials":1178,"activeCount":58},[],{"trials":1180,"activeCount":58},[],{"trials":1182,"activeCount":58},[],{"trials":1184,"activeCount":58},[],{"intervention":1176,"totalTrials":54,"cells":1186},{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1195,"PHASE3":1197,"PHASE4":1199,"NA":1201},{"trials":1188,"activeCount":58},[],{"trials":1190,"activeCount":58},[1191],{"nctId":1170,"briefTitle":1171,"status":167,"phases":1192,"primaryCompletion":475,"completion":475,"start":1173,"enrollment":476,"conditions":1193,"interventions":1194},[47],[23],[1163,1176],{"trials":1196,"activeCount":58},[],{"trials":1198,"activeCount":58},[],{"trials":1200,"activeCount":58},[],{"trials":1202,"activeCount":58},[],{"intervention":1204,"totalTrials":54,"cells":1205},"2141 V-11",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1221,"PHASE3":1223,"PHASE4":1225,"NA":1227},{"trials":1207,"activeCount":58},[],{"trials":1209,"activeCount":58},[1210],{"nctId":1211,"briefTitle":1212,"status":167,"phases":1213,"primaryCompletion":1214,"completion":1214,"start":1215,"enrollment":269,"conditions":1216,"interventions":1220},"NCT04059588","A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin",[47],"2023-03-13","2020-01-16",[1217,1218,1219],"Cancer","Solid Tumor","Cancer of Skin",[1204],{"trials":1222,"activeCount":58},[],{"trials":1224,"activeCount":58},[],{"trials":1226,"activeCount":58},[],{"trials":1228,"activeCount":58},[],{"intervention":1230,"totalTrials":605,"cells":1231},"Brodalumab",{"EARLY_PHASE1":1232,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1233,"activeCount":58},[1234,1244,1254],{"nctId":1235,"briefTitle":1236,"status":167,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":31,"conditions":1240,"interventions":1243},"NCT04979520","Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa",[46],"2022-07-25","2021-08-05",[1241,1242],"Hidradenitis Suppurativa","Acne Inversa",[1230],{"nctId":1245,"briefTitle":1246,"status":1247,"phases":1248,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":58,"conditions":1252,"interventions":1253},"NCT04249713","An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab","WITHDRAWN",[46],"2020-07","2020-09","2020-02-03",[1241],[1230],{"nctId":1255,"briefTitle":1256,"status":167,"phases":1257,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":194,"conditions":1260,"interventions":1261},"NCT03960268","Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab",[46],"2020-06-01","2019-05-28",[1241],[1230],{"trials":1263,"activeCount":58},[],{"trials":1265,"activeCount":58},[],{"trials":1267,"activeCount":58},[],{"trials":1269,"activeCount":58},[],{"trials":1271,"activeCount":58},[],{"intervention":1273,"totalTrials":54,"cells":1274},"Actimmune",{"EARLY_PHASE1":1275,"PHASE1":1286,"PHASE2":1288,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1276,"activeCount":58},[1277],{"nctId":1278,"briefTitle":1279,"status":116,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":9,"conditions":1283,"interventions":1285},"NCT01317017","Cell Responses to IFN-gamma",[46],"2011-05","2010-07",[1284],"Plaque Psoriasis",[1273],{"trials":1287,"activeCount":58},[],{"trials":1289,"activeCount":58},[],{"trials":1291,"activeCount":58},[],{"trials":1293,"activeCount":58},[],{"trials":1295,"activeCount":58},[],{"intervention":1297,"totalTrials":54,"cells":1298},"IM Pneumococcal, meningococcal, or flu vaccine",{"EARLY_PHASE1":1299,"PHASE1":1309,"PHASE2":1311,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1300,"activeCount":58},[1301],{"nctId":1302,"briefTitle":1303,"status":116,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":475,"enrollment":1306,"conditions":1307,"interventions":1308},"NCT01967238","An Open Label Study of IgG Fc Glycan Composition in Human Immunity",[46],"2023-03",129,[27],[1297],{"trials":1310,"activeCount":58},[],{"trials":1312,"activeCount":58},[],{"trials":1314,"activeCount":58},[],{"trials":1316,"activeCount":58},[],{"trials":1318,"activeCount":58},[],{"intervention":1320,"totalTrials":54,"cells":1321},"Guselkumab",{"EARLY_PHASE1":1322,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1339},{"trials":1323,"activeCount":58},[1324],{"nctId":1325,"briefTitle":1326,"status":1247,"phases":1327,"primaryCompletion":1328,"completion":1328,"start":1258,"enrollment":58,"conditions":1329,"interventions":1330},"NCT04084665","Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.",[46],"2020-07-30",[1241],[1320],{"trials":1332,"activeCount":58},[],{"trials":1334,"activeCount":58},[],{"trials":1336,"activeCount":58},[],{"trials":1338,"activeCount":58},[],{"trials":1340,"activeCount":58},[],{"intervention":1342,"totalTrials":54,"cells":1343},"Celebrex",{"EARLY_PHASE1":1344,"PHASE1":1354,"PHASE2":1356,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1345,"activeCount":58},[1346],{"nctId":1347,"briefTitle":1348,"status":167,"phases":1349,"primaryCompletion":1350,"completion":1350,"start":1351,"enrollment":194,"conditions":1352,"interventions":1353},"NCT01901679","Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women",[46],"2014-08","2013-07",[14],[1342],{"trials":1355,"activeCount":58},[],{"trials":1357,"activeCount":58},[],{"trials":1359,"activeCount":58},[],{"trials":1361,"activeCount":58},[],{"trials":1363,"activeCount":58},[],{"intervention":1365,"totalTrials":54,"cells":1366},"Vitamin D3",{"EARLY_PHASE1":1367,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1368,"activeCount":58},[1369],{"nctId":1370,"briefTitle":1371,"status":167,"phases":1372,"primaryCompletion":426,"completion":1373,"start":1374,"enrollment":452,"conditions":1375,"interventions":1377},"NCT00772772","Vitamin D Repletion in Chronic Kidney Disease",[46],"2009-10","2008-03",[1376],"Chronic Kidney Disease",[1365],{"trials":1379,"activeCount":58},[],{"trials":1381,"activeCount":58},[],{"trials":1383,"activeCount":58},[],{"trials":1385,"activeCount":58},[],{"trials":1387,"activeCount":58},[],{"intervention":1389,"totalTrials":9,"cells":1390},"Diphenylcyclopropenone",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1405,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1392,"activeCount":58},[],{"trials":1394,"activeCount":58},[1395],{"nctId":1396,"briefTitle":1397,"status":167,"phases":1398,"primaryCompletion":1399,"completion":1399,"start":1400,"enrollment":8,"conditions":1401,"interventions":1404},"NCT01711684","Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)",[47],"2015-06-22","2012-10-16",[1402,1403],"Neoplasm Metastasis","Melanoma",[1389],{"trials":1406,"activeCount":58},[],{"trials":1408,"activeCount":58},[],{"trials":1410,"activeCount":58},[],{"trials":1412,"activeCount":58},[1413],{"nctId":1414,"briefTitle":1415,"status":167,"phases":1416,"primaryCompletion":1417,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1421},"NCT01452594","Analysis of Diphenylcyclopropenone (DPCP) in Normals",[],"2013-09","2011-10",30,[23],[1389],{"intervention":1423,"totalTrials":9,"cells":1424},"Maraviroc",{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1426,"activeCount":58},[],{"trials":1428,"activeCount":58},[1429],{"nctId":1430,"briefTitle":1431,"status":167,"phases":1432,"primaryCompletion":1281,"completion":1281,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1436},"NCT00703586","Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc",[47],"2007-09",8,[17],[1423],{"trials":1438,"activeCount":58},[],{"trials":1440,"activeCount":58},[],{"trials":1442,"activeCount":58},[],{"trials":1444,"activeCount":58},[1445],{"nctId":1446,"briefTitle":1447,"status":167,"phases":1448,"primaryCompletion":517,"completion":517,"start":1449,"enrollment":428,"conditions":1450,"interventions":1451},"NCT00525733","Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)",[51],"2007-10",[17],[1452,1453,1423,1454,1455],"darunavir 800 mg","FTC 200 mg\u002FTDF 300mg","Raltegravir","Ritonavir 100 mg",{"intervention":1457,"totalTrials":9,"cells":1458},"Etanercept",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1475,"NA":1477},{"trials":1460,"activeCount":58},[],{"trials":1462,"activeCount":58},[],{"trials":1464,"activeCount":58},[],{"trials":1466,"activeCount":58},[1467],{"nctId":1468,"briefTitle":1469,"status":167,"phases":1470,"primaryCompletion":1471,"start":1472,"enrollment":1419,"conditions":1473,"interventions":1474},"NCT00116181","Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis",[49],"2007-01","2004-10",[20],[1457],{"trials":1476,"activeCount":58},[],{"trials":1478,"activeCount":58},[1479],{"nctId":1480,"briefTitle":1481,"status":167,"phases":1482,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":1485,"conditions":1486,"interventions":1487},"NCT01170715","Psoriasis Inflammation and Systemic Co Morbidities",[51],"2013-09-09","2010-07-13",29,[20],[1457],{"intervention":1489,"totalTrials":9,"cells":1490},"Hepatitis B Vaccine",{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1509},{"trials":1492,"activeCount":58},[],{"trials":1494,"activeCount":58},[],{"trials":1496,"activeCount":58},[],{"trials":1498,"activeCount":58},[],{"trials":1500,"activeCount":58},[1501],{"nctId":1502,"briefTitle":1503,"status":116,"phases":1504,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":18,"conditions":1507,"interventions":1508},"NCT05272735","HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers",[50],"2025-09-29","2022-12-10",[69],[1489],{"trials":1510,"activeCount":58},[1511],{"nctId":1512,"briefTitle":1513,"status":167,"phases":1514,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":194,"conditions":1517,"interventions":1518},"NCT02055365","Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers",[51],"2015-01-06","2014-02-18",[69],[1489],{"intervention":1520,"totalTrials":54,"cells":1521},"Tacrolimus",{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1532},{"trials":1523,"activeCount":58},[],{"trials":1525,"activeCount":58},[],{"trials":1527,"activeCount":58},[],{"trials":1529,"activeCount":58},[],{"trials":1531,"activeCount":58},[],{"trials":1533,"activeCount":58},[1534],{"nctId":1535,"briefTitle":1536,"status":167,"phases":1537,"primaryCompletion":1538,"completion":1538,"start":1539,"enrollment":258,"conditions":1540,"interventions":1542},"NCT00378326","Immunotherapy of the Paraneoplastic Syndromes",[51],"2014-05","2006-04",[1541],"Paraneoplastic Syndromes",[1520],{"intervention":1544,"totalTrials":54,"cells":1545},"Yellow Fever Vaccine",{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1547,"activeCount":58},[],{"trials":1549,"activeCount":58},[],{"trials":1551,"activeCount":58},[],{"trials":1553,"activeCount":58},[],{"trials":1555,"activeCount":58},[],{"trials":1557,"activeCount":58},[1558],{"nctId":1559,"briefTitle":1560,"status":167,"phases":1561,"primaryCompletion":1562,"completion":1562,"start":1563,"enrollment":8,"conditions":1564,"interventions":1565},"NCT03458780","Yellow Fever Immune Response at Single Cell Resolution",[],"2018-09-05","2016-08-22",[27],[1544],{"intervention":1567,"totalTrials":54,"cells":1568},"Zoster vaccine live",{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1575,"PHASE4":1577,"NA":1579},{"trials":1570,"activeCount":58},[],{"trials":1572,"activeCount":58},[],{"trials":1574,"activeCount":58},[],{"trials":1576,"activeCount":58},[],{"trials":1578,"activeCount":58},[],{"trials":1580,"activeCount":58},[1581],{"nctId":1582,"briefTitle":1583,"status":116,"phases":1584,"primaryCompletion":1585,"completion":1585,"start":1586,"enrollment":145,"conditions":1587,"interventions":1588},"NCT02590068","Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination",[51],"2017-09-08","2015-12",[30],[1567],{"intervention":1590,"totalTrials":54,"cells":1591},"Antiretroviral therapy",{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1598,"PHASE4":1600,"NA":1602},{"trials":1593,"activeCount":58},[],{"trials":1595,"activeCount":58},[],{"trials":1597,"activeCount":58},[],{"trials":1599,"activeCount":58},[],{"trials":1601,"activeCount":58},[],{"trials":1603,"activeCount":58},[1604],{"nctId":1605,"briefTitle":1606,"status":167,"phases":1607,"primaryCompletion":1608,"completion":1608,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1612},"NCT00219934","Observational Study of Treated and Untreated Acute and Early HIV-1 Infection",[],"2010-11","2002-02",399,[17],[1590],{"intervention":1614,"totalTrials":54,"cells":1615},"Influenza vaccine",{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1622,"PHASE4":1624,"NA":1626},{"trials":1617,"activeCount":58},[],{"trials":1619,"activeCount":58},[],{"trials":1621,"activeCount":58},[],{"trials":1623,"activeCount":58},[],{"trials":1625,"activeCount":58},[],{"trials":1627,"activeCount":58},[1628],{"nctId":1629,"briefTitle":1630,"status":116,"phases":1631,"primaryCompletion":1632,"completion":1632,"start":853,"enrollment":280,"conditions":1633,"interventions":1636},"NCT02653495","Impact of Metabolic Syndrome on Flu Vaccine Efficacy",[51],"2017-03",[1634,1635],"Immune Deficiency","Metabolic Syndrome",[1614],{"intervention":1452,"totalTrials":54,"cells":1638},{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1649},{"trials":1640,"activeCount":58},[],{"trials":1642,"activeCount":58},[],{"trials":1644,"activeCount":58},[],{"trials":1646,"activeCount":58},[],{"trials":1648,"activeCount":58},[],{"trials":1650,"activeCount":58},[1651],{"nctId":1446,"briefTitle":1447,"status":167,"phases":1652,"primaryCompletion":517,"completion":517,"start":1449,"enrollment":428,"conditions":1653,"interventions":1654},[51],[17],[1452,1453,1423,1454,1455],{"intervention":1453,"totalTrials":54,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1658,"activeCount":58},[],{"trials":1660,"activeCount":58},[],{"trials":1662,"activeCount":58},[],{"trials":1664,"activeCount":58},[],{"trials":1666,"activeCount":58},[],{"trials":1668,"activeCount":58},[1669],{"nctId":1446,"briefTitle":1447,"status":167,"phases":1670,"primaryCompletion":517,"completion":517,"start":1449,"enrollment":428,"conditions":1671,"interventions":1672},[51],[17],[1452,1453,1423,1454,1455],{"intervention":1454,"totalTrials":54,"cells":1674},{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1676,"activeCount":58},[],{"trials":1678,"activeCount":58},[],{"trials":1680,"activeCount":58},[],{"trials":1682,"activeCount":58},[],{"trials":1684,"activeCount":58},[],{"trials":1686,"activeCount":58},[1687],{"nctId":1446,"briefTitle":1447,"status":167,"phases":1688,"primaryCompletion":517,"completion":517,"start":1449,"enrollment":428,"conditions":1689,"interventions":1690},[51],[17],[1452,1453,1423,1454,1455],{"intervention":1455,"totalTrials":54,"cells":1692},{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1699,"PHASE4":1701,"NA":1703},{"trials":1694,"activeCount":58},[],{"trials":1696,"activeCount":58},[],{"trials":1698,"activeCount":58},[],{"trials":1700,"activeCount":58},[],{"trials":1702,"activeCount":58},[],{"trials":1704,"activeCount":58},[1705],{"nctId":1446,"briefTitle":1447,"status":167,"phases":1706,"primaryCompletion":517,"completion":517,"start":1449,"enrollment":428,"conditions":1707,"interventions":1708},[51],[17],[1452,1453,1423,1454,1455],{"intervention":1710,"totalTrials":54,"cells":1711},"Petrolatum application under occlusion",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1713,"activeCount":58},[],{"trials":1715,"activeCount":58},[],{"trials":1717,"activeCount":58},[],{"trials":1719,"activeCount":58},[],{"trials":1721,"activeCount":58},[],{"trials":1723,"activeCount":58},[1724],{"nctId":1725,"briefTitle":1726,"status":167,"phases":1727,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":315,"conditions":1730,"interventions":1732},"NCT02338076","A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin",[51],"2015-02","2013-06",[1731],"Skin Disease",[1710],{"intervention":1734,"totalTrials":54,"cells":1735},"Interleukin-2, Polyethylene Glycolated",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1737,"activeCount":58},[],{"trials":1739,"activeCount":58},[],{"trials":1741,"activeCount":58},[],{"trials":1743,"activeCount":58},[],{"trials":1745,"activeCount":58},[],{"trials":1747,"activeCount":58},[1748],{"nctId":1749,"briefTitle":1750,"status":167,"phases":1751,"conditions":1752,"interventions":1753},"NCT00002017","Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2",[51],[17],[1734],{"intervention":1755,"totalTrials":54,"cells":1756},"Thalidomide",{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1758,"activeCount":58},[],{"trials":1760,"activeCount":58},[],{"trials":1762,"activeCount":58},[],{"trials":1764,"activeCount":58},[],{"trials":1766,"activeCount":58},[],{"trials":1768,"activeCount":58},[1769],{"nctId":1770,"briefTitle":1771,"status":167,"phases":1772,"enrollment":452,"conditions":1773,"interventions":1774},"NCT00002392","A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART",[51],[17],[1755],{"intervention":1776,"totalTrials":54,"cells":1777},"Cyclosporine A",{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1779,"activeCount":58},[],{"trials":1781,"activeCount":58},[],{"trials":1783,"activeCount":58},[],{"trials":1785,"activeCount":58},[],{"trials":1787,"activeCount":58},[],{"trials":1789,"activeCount":58},[1790],{"nctId":1791,"briefTitle":1792,"status":167,"phases":1793,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":18,"conditions":1796,"interventions":1798},"NCT01149759","Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy",[51],"2014-12","2010-06",[478,1797],"Eczema",[1776]]